Amarin Co. ADR Logo
US0231112063
A0NBNG
AMRN

Amarin Co. ADR

Loading quotes...

Forecast

The analysts' average price target is €1.98 (-80.68%). The median is €1.82 (-82.24%).

Buy
  3
Hold
  13
Sell
  2

Discussions in the community

  • Ticker Symbol neben ISIN und WKN

    OM Olaf MĂĽller IV in Portfolio Tracking

    3 2

  • Amarin reports 42% revenue decline after missing prior-year license payment

    Amarin reported a 42% decline in net revenues for Q2, mainly due to the absence of a $25m license prepayment from Recordati in the prior-year period. Operating expenses fell 59% to $27m after completing a $70m cost‑reduction initiative. US sales of VASCEPA decreased slightly because of generic competition and net price pressure, partly offset by demand; the company recorded its third consecutive quarter of positive cash flow and expects international growth, stable US sales volumes, positive cash flow and a 10% increase in liquid funds by the end of 2026. » More on de.investing.com


  • Amarin emphasizes cost advantage of VASCEPA after approval of new injectable therapies

    Amarin clarifies that VASCEPA remains a treatment option for severe hypertriglyceridemia and reduced triglycerides by a median of 33% versus placebo. About 50% of patients reached levels below 500 mg/dL after 12 weeks. The company highlights that the annual wholesale prices of the new injectable APOC3 therapies are around $40,000, while VASCEPA costs about $4,200 per patient. Amarin also points to over 30 million prescriptions and the cardiovascular approval in combination with statins. » More on de.investing.com


  • Amarin shareholders block share issuances and restrict equity compensation

    Amarin shareholders rejected several key proposals, including the renewal of the authorization to issue new shares, an increase in the reserve under the 2020 Stock Incentive Plan, and the issuance of shares without UK pre-emption rights. While the re-election of several board members and the advisory approval of executive pay were passed, they received lower support levels. The board warns this will severely limit the grant of equity-based incentives, make future variable pay primarily cash‑based, and incur additional costs for paper shareholder communications. Shareholders approved the appointment of Ernst & Young as auditor for fiscal year 2026. » More on de.investing.com


  • Amarin increases sales and reduces operating loss through restructuring

    Amarin reported a 7.4% increase in total net revenue for Q1 2026 to $45.1 million and, thanks to restructuring measures, cut operating expenses by 31%. The operating loss fell 32.7% to $11.3 million. The company generated positive cash flow for the second consecutive quarter ($6.4 million) and held $308 million in cash at quarter-end. Vascepa prescriptions in the US rose 17%, and the partnership with Recordati contributed to strong revenue growth in Europe. Amarin expects positive full-year cash flow for 2026 and forecasts Q2 EPS of $0.54, but notes risks from generic competition and regulatory hurdles. » More on de.investing.com


  • Amarin to release quarterly results on Feb. 25, 2026

    Amarin will release results for the quarter ended Dec. 31, 2025 on Feb. 25, 2026. Three analysts see an average EPS of $0.034 per share, after a loss of -$2.380 in the year-ago quarter. The consensus expects quarterly revenue of $54.6 million (‑11.6% vs. $61.7 million a year earlier). For the fiscal year, three analysts on average forecast a loss of -$0.661 per share and revenue of $222.5 million compared with $228.7 million the prior year. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2012, Amarin Co. ADR has already paid €0.0939 in dividends. The last payout was in October 2012.

Financials

In the last quarter, Amarin Co. ADR had revenue of €34.92M and net profit of €216.3K
(EUR) September 2026
YoY
Revenue 34.92M 17.50%
Gross profit 14.29M 24.51%
Net profit 216.3K 103.28%
EBITDA 842.24K 219.08%

Fundamentals

Metric Value
Market capitalization
€213.04M
Number of shares
20.68M
52-week high/low
€15.76 - €10.25
Dividends No
Beta
0.79
P/E ratio
-10.80
PEG ratio
-0.07
P/B ratio
0.53
P/S ratio
1.33

Company profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Name
Amarin Co. ADR
CEO
Aaron D. Berg
Headquarters Dublin, du
Ireland
Website
Sector
Materials
Industry
Chemicals
IPO
04/01/1993
Employees 80

Ticker symbols

Exchange Symbol
NASDAQ
AMRN
Frankfurt
EH3A.F
DĂĽsseldorf
EH3A.DU
MĂĽnchen
EH3A.MU
🍪

Parqet  uses cookies. Learn more